Prince Street Capital Management LLC Bei Gene, Ltd. Transaction History

Prince Street Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$107.01 - $175.15 $6.72 Million - $11 Million	-62,800 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $1.91 Million - $2.37 Million	12,500 Added 24.85%	62,800 $10.8 Million
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $38.9 Million - $55.3 Million	-255,200 Reduced 83.54%	50,300 $7.73 Million
Q1 2018 May 14, 2018	SELL	$97.41 - $177.22 $4.41 Million - $8.03 Million	-45,300 Reduced 12.91%	305,500 $51.3 Million
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $398,000 - $573,650	5,000 Added 1.45%	350,800 $34.3 Million
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $22.9 Million - $35.8 Million	345,800	345,800 $35.8 Million

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Prince Street Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Prince Street Capital Management LLC with notifications on news.